Contenu connexe Similaire à Precision Medicine: Opportunities and Challenges for Clinical Trials (20) Precision Medicine: Opportunities and Challenges for Clinical Trials1. Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
1
2. What Is Precision Medicine?
o National Research Council (2011)
“Tailoring of disease prevention and treatment
based on the characteristics of each individual”
Old idea, but new implications due to new
technology that allows for the analysis of large
scale genomic data
3. What Is Precision Medicine?
3 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o President Obama’s Precision Medicine Initiative
(2015)
“……an innovative approach to disease prevention
and treatment that takes into account individual
differences in people’s genes, environments and
lifestyles.”
4. Precision Medicine Initiative
4 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o President’s 2016 budget
$216 million
o Goals:
Develop more and better treatments for cancer
Create a national voluntary research cohort
Protect privacy
Modernize regulation
Develop public-private partnerships
5. Precision Medicine: Core Premise
o “The application of evidence-based medicine can
improve quality and control cost in a healthcare
system”
Aronson N, Annals NY Acad of Sci 2015
Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
5
6. Precision Medicine: Core Premise
o Simplistic impression
Do a test (e.g., sequence the genome of a tumor)
Identify “actionable” target(s)
Pick a drug (approved or experimental) for the
identified target(s)
Aronson N, Annals NY Acad of Sci 2015
Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
6
7. Precision Medicine: Core Premise
o Likely more complex than this
Diagnostic test performance
Test interpretation
Multiple targets
Prioritization of targets (e.g., which are drivers)
Number of targets that are “actionable”
Availability of approved or experimental drugs
• Drugs need to be tested in patients with specific
abnormalities and proven to be effective
• Drug needs to be proven safe and effective if used in
combination
Clinical decision making and management
Healthcare delivery variables
Measuring treatment outcomes
Aronson N, Annals NY Acad of Sci 2015
Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
7
8. Precision Medicine: Goals
8 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o Determine:
How do we better target driver (central oncogenic
event)abnormalities?
Who will respond to treatment?
Who will not respond to treatment?
How can we reduce harm associated with
treatment, especially if the treatment does not
work?
How can we make treatments more cost effective
How can we improve access to better treatments?
Will molecular testing improve outcomes?
9. What Is Personalized Medicine?
o “Although the term personalized medicine is
repeated like a mantra in scientific papers,
meetings, media and even the Internet, its exact
definition is vague and remains almost unclear to
many.”
Giuseppe Lippi and Mario Plebani, Clin Chem Lab Med 2015
Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
9
10. Are Personalized Medicine and Precision
Medicine the Same?
10 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o Not clear
o Terms are often used interchangeably
o Clinical care versus clinical research
Physicians always personalize care
Clinical research requires “lumping of patients” to
some degree
• Results of clinical research are based on the mean
of the study population
• Relevance to an individual?
o Clinical care is increasing precise as knowledge
and technology advances
11. Are Personalized Medicine and Precision
Medicine New?
11 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o New terminology?
o Fad?
o Politics?
o Marketing?
o Media?
12. Strategy Is Not New!
12 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o These concepts and strategies have guided
cancer therapeutics for more than 60 years
o Example:
One of the greatest success stories in the history of
medicine: ALL in children
13. Childhood ALL: 10-Year Survival Estimates by
Year of Treatment
13 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
0
10
20
30
40
50
60
70
80
90
100
1968-
1970
1972-
1975
1978-
1983
1989-
1995
EstimatedSurvivalPercentage
14. How Did We Achieve These
Remarkable Improvements in
Outcome For Children With ALL?
14 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o Clinical trials have been increasingly precise and
personalized since the 1950’s
Biology!
Risk group identification
Risk group directed therapy
15. Frequency of cytogenetic subtypes of pediatric ALL.
Charles G. Mullighan Hematology 2012;2012:389-396
©2012 by American Society of Hematology
17. FDA Approval of Drugs Used To Treat ALL
17 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o Methotrexate 1953
o Mercaptopurine 1953
o Dexamethasone 1958
o Vincristine 1963
o Thioguanine 1966
o Cytarabine 1969
o Daunomycin 1979
o Etoposide 1983
o Asparaginase 1994
18. Smith M A et al. JCO 2010;28:2625-2634
Mortality Rates for Childhood Cancer
18 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
19. What Next?
19 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o Progress is slowing
o After almost 60 years, have
o we optimized therapy with
o current treatment?
o If so, what do we do next?
20. Effective Cancer Treatment
20 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o What has gotten us to this point?
Surgery
Radiation
Chemotherapy
Blood and marrow transplantation
o To make further improvements, we need to add
something new
These new treatments will be based on the biology
of the cancer and the patient
• For example, sequencing the genome
21. How Many Genes Are Involved In Cancer?
21 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o Current data suggest about 1% of genes have
mutations that are involved in cancer (less than
300)
Futreal PA, et al. “ A census of human cancer
genes”. Nature Rev Cancer 4:177-183, 2004
o Currently, only a relatively small subset of these
abnormalities are “actionable” (e.g., serve as drug
targets)
22. Excitement About Precision Medicine
22 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o BCR-ABL CML
Kantarjian H et al. “Hematologic and cytogenetic
responses to imatinib mesylate in chronic
myelogenous leukemia”. N Engl J Med 346:645-
656, 2002
o EGFR-mutant lung cancer
Paez JG et al. “EGFR mutations in lung cancer:
Correlation with clinical response to gefitinib
therapy”. Science 304: 1497-1500, 2004
o ERBB2+ breast cancer
Romond EH et al. “Trastuzumab plus adjuvant
chemotherapy for operable HER2-positive breast
cancer”. N Engl J Med 353: 1673-1684, 2005
23. Process-To-Date
23 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o Identification of genomic alterations in patients
with a specific diagnosis
o The genomic alteration is a driver (central) of the
oncogenic event
o Activity of the targeted drug has been tested
against the target in pre-clinical and early phase
human clinical trials
24. Central Question For Precision Medicine
24 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o Is this same approach effective regardless of the
patient’s conventionally defined diagnosis?
25. Current Landscape
o Adult interventional cancer trials registered on
clinicaltrials.gov
o September 2005-May 2013
o Trial is classified as “precision cancer medicine” if
a genomic alteration in a predefined set of 88
genes was required for enrollment
Roper N et al Cancer Treatment Rev 2015
Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
25
26. Precision Medicine Studies
o 18,797 trials identified
9094 (48%) were eligible for inclusion
684 (8%) were classified as “precision cancer
medicine” trials
o Increase from 3% of trials in 2006 to 16% in 2013
o Most often involved breast, colorectal and skin
cancer
o Required 38 unique genomic alterations for
enrollment
Roper N et al Cancer Treatment Rev 2015
Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
26
27. New Actionable Targets: Example
o “Comprehensive Genomic Profiling of Carcinoma
of Unknown Primary (CUP) Site: New Routes to
Targeted Therapy”
Objective
• “To discover opportunities for targeted therapies in
patients with CUP not currently searched for in
routine practice
200 patients with CUP
Results
• Abnormalities found in 217 genes
» 30 clinically relevant
• Almost all CUP samples had a least 1 clinically
relevant genomic alteration (mean=4.1)
Ross JS et al JAMA Oncol 2015
Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
27
28. Is This Approach Feasible?
o “Feasibility of Large-Scale Genomic Testing to
Facilitate Enrollment Onto Genomically Matched
Clinical Trials”
2000 patients with advanced cancer
Broad-based genomic testing
Results
• 35 genes were “actionable”
• 39% of patients had at least 1 mutation in one of
these genes
• 11% of patients enrolled in a genotype-matched trial
targeting these alterations
Meric-Bernstam et al J Clin Oncol, Epub ahead of print 2015
Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
28
29. Novel Study Designs
o Basket Trials
Test treatments based on mechanism of action (as
opposed to histology)
o Umbrella Trials
Test multiple drugs for a single disease
o Adaptive Trials
Match treatment to patients during the conduct of
the study based on responses
Schork NJ Nature 2015
Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
29
30. Novel Study Designs
o Registries/Databases
Precision Medicine Initiative
“In silico” research
o N-of-1clinical trials
Require massive amounts of data on the individual
patient
Schork NJ Nature 2015
Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
30
31. Are Basket Designs Feasible?
o 647 patients with advanced thoracic malignancies
o 88% had tumors assessed for at least 1 gene
o EGFR mutation frequency was 22.1% in NSCLC
with 60% response rate to erlotinib
o KRAS mutation frequency 24.9% in NSCLC with
selumetinib failed to reach its primary endpoint
with a response rate of 11%
o Completion of accrual to all other arms was not
feasible
Lopez-Chavez a et al. J Clin Oncol 33:1000-1007, 2015
31 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
32. Ongoing: National Cancer Institute-Sponsored
Precision Medicine Clinical Trials
32 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o NCI-Match
ECOG-ACRIN
3000 patients with solid tumors and lymphoma
200 genes will be analyzed
40 drugs from 20 pharmaceutical companies
pledged
33. Ongoing: National Cancer Institute-Sponsored
Precision Medicine Clinical Trials
33 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o Lung-MAP
Phase II/III clinical trial
Patients with advanced squamous cell lung cancer
Genomic analysis
Pairs patients to targeted agents based on results
34. What is Fueling Recent Progress in
Precision Medicine?
34 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o Biology
Genomics
• High-throughput deep sequencing
• Just a few years ago, 1 genome sequenced in 2
weeks
• Now, >100 genomes per day
o Ability to store massive amounts of data
inexpensively (DeGennaro, L Personal
communication)
Storage of 1 gigabyte of data
• 1985: $71,000
• 2015: $0.03
o Ability to analyze large data sets
35. Challenges
35 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o Limited number of pathways identified
o Limited number of genes
o Limited number of “actionable” genes
o Focus on the genome is likely overly simplistic
o Ability to analyze data across multiple platforms
New models of disease
37. Challenges
37 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o Profound number of potential targets
Which targets are important?
How many targets are “actionable”?
Can targets be made actionable?
How many targets do you need to hit?
Will the targeted therapy kill only the susceptible
clones?
Prioritization of targets and drugs
Availability of clinical trials
38. Challenges
38 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o Targeted agents are highly unlikely to work as
single agents in cancer
o Use in combination with other targeted agents or
conventional therapies is highly likely
o Safe and effective use of targeted drugs in
combination is still predicated upon Phase I, II
and III safety and efficacy studies
39. Challenges
39 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o Will precision medicine reduce healthcare costs?
Spending on genetic and molecular testing
• $15-25 billion by 2021
» United Health Center for Health Reform &
Modernization, 2012
o Equity
Will it be available to only the “rich”
40. Challenges
40 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o Implications of knowing a person’s genome
sequence
Ethical
Legal
Financial
Social
41. Challenges
41 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o While medicine will continue to be increasingly
precise, what are the limits on truly “personalized”
treatment?
Are N-of-1 trials realistic, safe, effective and
informative?
42. What Kind of CRO’s Will Be Important In the
Development and Execution of
These Complex Studies?
42 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o Full service
Ability to integrate all required elements of a
complex study
o Physician-led
Medical and scientific knowledge and expertise
CRO’s that have recruited disease-specific KOL’s to
work for them
o Biostatistics and data management
Novel study designs
o IT infrastructures
Big data
o Regulatory experts
43. Summary
43 Physician Led | Therapeutically Focused
© 2015 Medpace, Inc. All Rights Reserved
o Biologic understanding of disease is advancing at a
remarkable pace
o Improvements in the outcome of patients is
undoubtedly going to follow
o The “precision medicine approach” is more complex
than most understand
Feasibility still being assess
o It is still highly experimental and in the end will still
require Phase I, II and III studies to establish safety
and efficacy
o “Don’t try this at home” (e.g., outside the context of a
clinical trial) if the safety and efficacy of the approach
has not yet been proven
44. Q& A
Franklin O. Smith, III, M.D., FAAP, FACP,
Medpace Vice President, Medical Affairs,
Hematology and Oncology
f.smith@Medpace.com